Trending News

Caught in the Act: Practical and Legal Considerations When Executives’ Office Love Affair Exposed

Florida’s CHOICE Act Becomes Law, Enhancing Certain Non-Compete Agreements

Labor Secretary Lifts Abeyance on OFCCP Disability and Veteran Matters

In Case You Missed It: DOL Prohibited From Collecting Liquidated Damages in Wage & Hour Pre-Litigation Investigations

SEC’s New Concept Release on Foreign Private Issuer Standards

What Regulated Businesses Should Know About the Supreme Court’s Recent NEPA Decision

NEW ATDS BATTLEGROUND: Texas Passes HUGE NEW AMENDMENT to Its State Telemarketing Law Reviving The Risk of Autodialer Cases

Supreme Court Eliminates Heightened Discrimination Standard Under Title VII

Cleaning the Cupboard—Six More Decisions in One Day, and a Largely Harmonious Court - SCOTUS Today

U.S. Supreme Court Holds Majority-Group Plaintiffs Are Not Subject to a Heightened Evidentiary Standard Under Title VII

GlobeNewswire Biotech

Website

www.globenewswire.com

Featured Biotech Press Releases From GlobeNewswire

Applied Therapeutics Announces Acceptance of Late-Breaking Abstract for Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting
Posted On Friday, May 09, 2025
Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) at the 2025 PNS Meeting
Posted On Friday, May 09, 2025
BioCardia to Host Q1 2025 Corporate Update and Financial Results Conference Call on May 14, 2025
Posted On Friday, May 09, 2025
Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates
Posted On Friday, May 09, 2025
PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Posted On Friday, May 09, 2025
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Posted On Friday, May 09, 2025
Surrozen Reports First Quarter 2025 Financial Results and Provides Business Update
Posted On Friday, May 09, 2025
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Posted On Friday, May 09, 2025
Celularity Announces Full Year 2024 Operating and Financial Results
Posted On Friday, May 09, 2025
Conduit Pharmaceuticals Receives Further Patent Approval For Its Lead Asset Targeting Autoimmune Diseases
Posted On Friday, May 09, 2025
Ocugen Provides Business Update with First Quarter 2025 Financial Results
Posted On Friday, May 09, 2025
Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 13, 2025
Posted On Friday, May 09, 2025
PMV Pharmaceuticals Reports First Quarter 2025 Financial Results and Corporate Highlights
Posted On Friday, May 09, 2025
BlossomHill Therapeutics Appoints Jason Keyes as Chief Financial Officer and Executive Vice President
Posted On Friday, May 09, 2025
Garuda Therapeutics Announces Name Change to Stratus Therapeutics to Reflect Mission of Pioneering Full Hematopoietic System Renewal
Posted On Friday, May 09, 2025
Akero Therapeutics Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin in Patients with Compensated Cirrhosis Caused by MASH Showing Fibrosis Improvement without Worsening of MASH at the EASL Congress 2025
Posted On Friday, May 09, 2025
Spectral Medical Announces First Quarter and Provides Corporate Update
Posted On Friday, May 09, 2025
Cognition Therapeutics Presented Data at Association for Research in Vision and Ophthalmology Showing Impact on Retinal Cell Health
Posted On Friday, May 09, 2025
Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Trial in the New England Journal of Medicine
Posted On Friday, May 09, 2025
uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress
Posted On Friday, May 09, 2025
Clearside Biomedical Data Featured in Six Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting
Posted On Friday, May 09, 2025
Kymera Therapeutics Expands Industry Leading Immunology Pipeline with New First-in-Class, Oral IRF5 Degrader Program with Potential to Address Multiple Immuno-Inflammatory Diseases
Posted On Friday, May 09, 2025
Aclaris Therapeutics to Participate in the HC Wainwright “HCW@Home” Series
Posted On Friday, May 09, 2025
Kymera Therapeutics Announces First Quarter 2025 Financial Results and Provides a Business Update
Posted On Friday, May 09, 2025
OXB to Present at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
Posted On Friday, May 09, 2025

Print